The Rundown Eli Lilly Sounds Alarm on Copycat GLP-1s, Trouble Brewing in Private Credit
8 snips
Mar 12, 2026 Oil spikes past $100 as Mideast shipping disruptions shake markets. A major drugmaker warns about contaminated copycat weight-loss treatments and regulatory fights around compounded medicines heat up. Big private credit firms impose withdrawal limits amid rising redemption pressure and risky loans. A dating app unveils an AI matchmaker and a Hollywood AI startup lands a nine-figure buyout.
AI Snips
Chapters
Transcript
Episode notes
Strait Of Hormuz Supply Gap Is Driving Oil Higher
- Oil prices are climbing because the Strait of Hormuz is effectively closed after recent attacks, removing ~20 million barrels/day from global supply.
- The IEA's 400 million barrel strategic release covers only ~5 million barrels/day, leaving a large supply gap that keeps prices elevated.
Lilly Flags Toxicity In Compounded Trisepatide Products
- Eli Lilly found significant impurities in 10 samples of compounded trisepatide-B12 products and warned of potential toxicity and immune reactions.
- The company sued some compounders and alerted the FDA as copycat pharmacies exploit a loophole that tweaks formulas to sell Trisepatide.
Loophole Lets Copycats Persist Despite No Shortage
- Compound pharmacies continued selling copycat weight-loss drugs via a loophole that allows small formula tweaks despite resolved supply shortages.
- The FDA sent warning letters to 30 telehealth companies for misleading claims, and Lilly is pursuing legal action to protect market share.